Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-520716-34-00

Acronym

BLCL-RUX-FDA-01

Enrollment

Registered

2025-03-07

Start date

2025-03-17

Completion date

2025-04-30

Last updated

2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition.

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026